Aernoud Fiolet

110 Chapter 4 Trial (COLCOT) includes participants within 1 month of an acute myocardial infarction. 55 The Colchicine and Spironolactone in Patients With STEMI/ SYNERGY (CLEAR-Synergy) trial is using a 2x2 factorial design to examine the effect of colchicine and spironolactone in patients presenting within 24 hours of ST-elevation myocardial infarction who have had primary percutaneous coronary intervention. 56 Finally, the Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE) study focuses on the effect of low-dose colchicine in patients following a stroke of transient ischemic attack. 57 In summary, the LoDoCo2 Trial will provide information on the efficacy and safety of low-dose colchicine for secondary prevention in patients with stable coronary artery disease. ACKNOWLEDGMENTS In Australia, the study received seed funding from Sir Charles Gairdner Hospital (Research Advisory Committee of Sir Charles Gairdner Hospital and Osborne Park Group and Charlies Foundation for Research) and major funding from the National Health Medical Research Council of Australia (NHMRC project grant APP 1088455). Aspen Pharmacare Australia provided the colchicine and matching placebo tablets for the trial in Australia at no cost. Further support for infrastructure related to the day to day running of the trial has been provided by GenesisCare Australia. In the Netherlands, the study received starting funding from the Withering Stichting Nederland (WSN) foundation and from the members of the WCN. Additional funding was obtained by means of the Netherlands Organization for Health Research and Development and the Netherlands Heart Foundation (ZonMw, rediscovery theme in the Rational Pharmacotherapy program, Grant nr. 848015014). A pharma consortium consisting of Teva, Haarlem, Disphar, Baarn and Tiofarma, Oud-Beijerland, all in the Netherlands provided colchicine and matching placebo tablets at no cost, and in addition an unrestricted research grant. Investigators with number of participants randomized between parentheses: Australia: S.M. Nidorf (302), X.F. Xu (255), M.A Ireland (248), D. Latchem (195), A. Whelan (169), R. Hendriks (168), P. Salkani (143), I.W. Tan (96), A.G Thompson (95), A.M. Morton (74), B.E Hockings (72), P.L. Thompson (35), B. King (15).